Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease.
OBJECTIVE
This retrospective study aimed to determine the effects of diabetes on overall survival (OS) and cancer-specific survival (CSS) in patients with newly diagnosed colon cancers, with particular focus on the impact of diabetes on survival at each stage of colon cancer.


METHODS
From January 1999 to January 2008, 2762 consecutive patients diagnosed with colon cancer in Taipei Veterans General Hospital were enrolled. The general characteristics as well as presence of diabetes prior to colon cancer diagnosis were identified. Cox proportional hazard analyses were used for prognostic factors determination; and survival was analyzed using the Kaplan-Meier method with log-rank test.


RESULTS
A total of 469 patients (17%) had diabetes at diagnosis of colon cancer. Patients with diabetes had baseline characteristics comparable to those without diabetes with the exception that the patients with diabetes were older (>65 years). Diabetes significantly and negatively impacted OS and CSS in multivariate analyses. After adjusting for possible confounding factors, the prognostic impact of diabetes on OS and CSS was particularly significant in patients with stage II colon cancer.


CONCLUSIONS
Diabetes is a poor prognostic factor in patients with newly diagnosed colon cancer, and it may directly impact the tumor behavior of stage II disease. Further study is required to elucidate the underlying pathophysiologic mechanisms.
Huang
Yu-Chung
YC
Division of Hematology-Oncology, Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan.
Lin
Jen-Kou
JK
Chen
Wei-Shone
WS
Lin
Tzu-Chen
TC
Yang
Shung-Haur
SH
Jiang
Jeng-Kai
JK
Chang
Shih-Ching
SC
Lan
Yuan-Tzu
YT
Wang
Huann-Sheng
HS
Liu
Chun-Yu
CY
Yang
Ya-Wen
YW
Teng
Hao-Wei
HW
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology*; D003110:Colonic Neoplasms / Q000401:mortality* / Q000473:pathology*; D048909:Diabetes Complications / Q000401:mortality* / Q000473:pathology*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies
Clin Gastroenterol Hepatol. 2006 Mar;4(3):369-80
16527702
Oncogene. 2009 May 28;28(21):2152-62
19377512
Am J Epidemiol. 2004 Jun 15;159(12):1160-7
15191933
Diabetes Metab Res Rev. 2009 Jan;25(1):3-12
19145587
J Clin Oncol. 2003 Feb 1;21(3):433-40
12560431
Nat Rev Cancer. 2004 Aug;4(8):579-91
15286738
Br J Cancer. 2005 Jun 6;92(11):2076-83
15886696
JAMA. 2008 Dec 17;300(23):2754-64
19088353
J Natl Cancer Inst. 2002 Jul 3;94(13):972-80
12096082
J Clin Oncol. 2009 Jan 10;27(2):176-85
19064975
Diabetes Metab Res Rev. 1999 Sep-Oct;15(5):314-22
10585616
Diabetologia. 2007 Jul;50(7):1365-74
17476474
Am J Epidemiol. 1998 May 1;147(9):816-25
9583711
Arch Pathol Lab Med. 2000 Jul;124(7):979-94
10888773
J Clin Oncol. 2002 Jan 1;20(1):42-51
11773152
Int J Cancer. 2007 Aug 15;121(4):856-62
17397032
Cancer Detect Prev. 2006;30(5):466-72
17069990
Cancer Res. 2008 Jan 1;68(1):329-37
18172327
J Am Geriatr Soc. 2006 Dec;54(12):1898-904
17198496
JAMA. 1990 Sep 19;264(11):1444-50
2202842
Eur J Cancer. 2005 Dec;41(18):2887-95
16243513
J Clin Oncol. 2004 Aug 15;22(16):3408-19
15199089
Cancer Causes Control. 2005 Jun;16(5):561-72
15986111
Diabetes. 2002 Aug;51(8):2629-36
12145180
Br J Cancer. 2009 Mar 10;100(5):795-8
19190630
Int J Cancer. 2007 May 1;120(9):1986-92
17230509
J Clin Oncol. 2004 May 15;22(10):1797-806
15067028
Med Oncol. 2006;23(4):515-9
17303910
J Clin Oncol. 2006 Nov 1;24(31):5017-24
17075121